๐
Lytenava
bevacizumab
Wet Macular Degeneration
โ
Authorised
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Lytenava is indicated in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/lytenava